ACLF Phase 2a

GENFIT plans to initiate a Phase 2a proof‑of‑concept study in Acute‑on‑Chronic Liver Failure (ACLF) in the fourth quarter of 2026, with data readout targeted in 2027. The existing regulatory and CMC packages for nangibotide are well advanced to support rapid clinical development in ACLF. This acquisition reinforces GENFIT's portfolio of innovative therapies addressing high unmet medical needs and positions the Company for leadership in the field of ACLF. The Company will provide more details on the program during The Liver Meeting in Denver in November 2026.